Ascertainment of cause-specific mortality in COPD: Operations of the TORCH Clinical Endpoint Committee

Thorax

Volumn 62, Issue 5, 2007, Pages 411-415

  McGarvey, Lorcan P ^a   John, Matthias ^b   Anderson, Julie A ^c   Zvarich, Michael ^d   Wise, Robert A ^e  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Respiratory Medicine   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GlazoSmithKline   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE; PLACEBO; SALMETEROL;

ARTICLE; CANCER; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE;

CAUSE OF DEATH; CONSENSUS; DOUBLE-BLIND METHOD; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 34247854749     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.072348     Document Type: Article

References (33)

1. NHLBI. NHLBI morbidity and mortality chartbook, 2004.Available at http://www.nhlbi.nih.gov/resources/docs/cht-book.htm (accessed 13 February 2005).
2. Wise RA. Changing smoking patterns and mortality from chronic obstructive pulmonary disease. Prev Med 1997;26:418-21.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
4. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8.
5. Anon. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of me Medical Research Council Working Party. Lancet 1981;1:681-6.
6. Vestbo J, TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004;24:206-10.
7. 1. The Lung Health Study. JAMA 1994;272:1497-505.
8. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of smoking cessation intervention on 14. 5-year mortality: a randomized clinical trial, Ann Intern Med 2005;142:233-9.
9. Afessa B, Morales IJ, Scanlon PD, et al. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med 2002;30:1610-5.
10. Fleiss J. Statistical methods for rates and proportions, 2nd ed. New York: Wiley, 1981.
11. Mahaffey KW, Roe MT, Dyke CK, et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. Am Heart J 2002;143:242-8.
12. Mahaffey KW, Harrington RA, Akkerhuis M, for the PURSUIT Investigators, et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2001;2:187-94.
13. Mahaffey KW, Harrington RA, Akkerhuis M, for the PURSUIT Investigators, et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2001;2:180-6.
14. Naslund U, Grip L, Fischer-Hansen J, et al. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. Eur Heart J 1999;20:771-7.
15. Heagerty A, Deverly A, Palmer C, et al. The role of the critical event committee in a major cardiovascular outcome study. Blood Press 2002;11:339-44.
16. Lauer MS, Blackstone EH, Young JB, et al. Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol 1999;34:618-20.
17. Kestle J, Milner R, Drake D. An assessment of observer bias in the shunt design trial. Pediatr Neurosurg 1999;30:57-61.
18. Temple R, Pledger GW. The FDA's critique of the anturane reinfarction trial. N Engl J Med 1980;303:1488-92.
19. Epstein AE, Carlson MD, Fogoros RN, et al. Classification of death in antiarrhythmic trials. J Am Coll Cardiol 1996;27:433- 42.
20. Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol 2004;160:1152-8.
21. Moussa MA, Shafie MZ, Khogali MM, et al. Reliability of death certificate diagnoses. J Clin Epidemiol 1990;43:1285-95.
22. Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987;106:512-8.
23. Skillrud DM, Offord KP, Miller RD. The higher risk of lung cancer in chronic obstructive pulmonary disease. Ann Intern Med 1986;105:503-7.
24. Lange P, Nyboe J, Appleyard M, et al. Spirometric finding and mortality in never-smokers. J Clin Epidemiol 1990;43:867-73.
25. Zielinski J, MacNee W, Wedzicha J, et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997;52:43-7.
26. Janssens JP, Herrmann F, MacGee W, et al. Cause of death in older patients with anatomo-pathological evidence of chronic bronchitis or emphysema: a case-control study based on autopsy findings. J Am Geriatr Soc 2001;49:571-6.
27. Higgins MW, Keller JB. Trends in COPD morbidity and mortality in Tecumseh, Michigan. Am Rev Respir Dis 1989;140:S42-8.
28. Vilkman S, Keistinen T, Tuuponen T, et al. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 1997;64:281-4.
29. Rajmil L, Plasencia A, Borrell C. Reproducibility of the use of classifications of causes of death in the context of inquiries in perinatal mortality (English abstract). An Esp Pediatr 1993;39:398-404.
30. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
31. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003;22:809-14.
32. Wren C, O'Sullivan JJ, Wright C. Sudden death in children and adolescents. Heart 2000;83:410-3.
33. Shachor Y, Liberman D, Tamir A, et al. Long-term survival of patients with chronic obstructive pulmonary disease following mechanical ventilation. Isr J Med Sci 1989;25:617-9.